Health News Releases

  • Today May 23
April 08, 2014 20:00
CEO Roundtable on Cancer Launches the Project Data Sphere Initiative, A New Data Sharing and Analytic Platform for Cancer Patient Benefit
Project Data Sphere, LLC (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), announced today the launch of a new data sharing platform (ww
April 08, 2014 18:35
FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)
For media outside of the U.S., the UK & Canada only Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate) for the treatm
April 08, 2014 13:40
Sun Pharma to Acquire Ranbaxy in a US$ 4 Billion Landmark Transaction
Sun Pharma and Ranbaxy today announced entering into definitive agreements for Sun Pharma to acquire 100% of Ranbaxy in an all-stock transaction. Under these agreements, Ranbaxy shareholders will rece
April 08, 2014 12:00
Bioventus Releases New EXOGEN® and Performance Guarantee in Canada
Bioventus, a global leader in active orthopaedic healing, today announced that the next generation of its market-leading[1] EXOGEN® Ultrasound Bone Healing System - including new compliance features a
Immunohistochemical analysis of paraffin-embedded human lung carcinoma using PD-L1 (E1L3N) XP® Rabbi
April 06, 2014 23:00
Cell Signaling Technology, Inc. Announces PD-L1 Antibody, Important to Cancer Immunotherapy Research
Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced today that it has introduced a highly specific PD-L1 rabbit monoclonal antibody (mAb). Recent reports have shown PD-L1 to be up-regulate
April 02, 2014 13:45
CROMA-PHARMA announced the signing of a significant Distribution Agreement with Asia´s leading Producer of Botulinum Toxins and Anti-Aging Products
Family owned, Austrian company CROMA-PHARMA announced today the signing of a 10 year comprehensive and important distribution agreement with Hugel Inc. of Korea. Hugel Inc. is the leading producer of
March 28, 2014 13:00
Quintiles Appoints Dr. Stella Blackburn to Lead Global Risk Management for Real-World & Late Phase Research
Quintiles today announced that Stella Blackburn, M.B. B.S., has been appointed as the vice president and global head of Risk Management for its Real-World & Late Phase Research group. In this role, Dr
March 28, 2014 10:00
Nature Genetics Founding Editor Kevin Davies Joins Pathway Genomics’ Scientific Advisory Board
Pathway Genomics Corporation (www.pathway.com), a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that Nature Genetics founding edi
March 27, 2014 12:00
Quintiles Announces Exercise of the Underwriters’ Option to Purchase Additional Secondary Shares
Quintiles today announced that the underwriters of the previously announced secondary public offering of 15 million shares of its common stock have exercised in full their option to purchase an additi
March 25, 2014 17:00
Otsuka Pharmaceutical‘s Samsca® Approved in Japan as the World’s First Drug Therapy for ADPKD, a Rare Kidney Disease
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kid
March 25, 2014 15:30
New Pradaxa® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session
For media outside of the US, the UK & Canada only Boehringer Ingelheim has today announced that new findings from ongoing Pradaxa® (dabigatran etexilate) research will be presented during the Ameri
March 25, 2014 14:00
Oral OTEZLA® (apremilast) Demonstrated Clinically Meaningful and Sustained Improvements in Skin, Nail and Scalp of Adult Patients with Moderate to Severe Plaque Psoriasis
Celgene Corporation (NASDAQ:CELG) today released new research findings on OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), from the ESTEEM 1 and 2 phase III
March 24, 2014 17:00
OTEZLA® (apremilast) - First Oral Therapy Approved by the U.S. Food and Drug Administration for the Treatment of Adults with Active Psoriatic Arthritis
Celgene Corporation (NASDAQ: CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (P
March 24, 2014 10:55
Type 2 Diabetes: CHMP recommends empagliflozin* for approval
Non-US and Non-UK Media Boehringer Ingelheim and Eli Lilly and Company are pleased to announce a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medi
March 24, 2014 10:50
Type 2 Diabetes: New poll of more than 700 Latin American physicians provides insights into complexity and challenges
Boehringer Ingelheim and Eli Lilly and Company today announced results from an online poll of more than 700 physicians treating people with Type 2 Diabetes (T2D) from across six Latin American countri
March 21, 2014 14:55
XPRIZE and TED Announce a Global Competition to Advance Artificial Intelligence
XPRIZE (www.xprize.org), the global leader in incentivized prize competitions, announces today the creation of a prize competition presented by TED, (www.TED.com), the nonprofit devoted to Ideas Worth
March 21, 2014 14:10
High-Speed Ultrasound Beamforming Source Driver From Supertex Delivers Sharper Images for Medical Ultrasound Applications
Supertex (NASDAQ: SUPX), a recognized leader in high voltage analog and mixed signal integrated circuits (ICs), introduces the MD2133, a high-speed source-driver for pulsed current applications. The M
March 20, 2014 09:00
Otsuka and The Union Announce Global TB Research & Innovation Award
In recognition of World TB Day 2014, Otsuka SA (Otsuka), in a global partnership with the International Union Against Tuberculosis and Lung Disease (The Union), today issued a call for nominations for
March 14, 2014 18:05
IntegenX Announces Approval to Upload DNA Profiles From the RapidHIT(TM) System to the National Database
IntegenX Inc., the market leader in Rapid Human DNA identification, has met the FBI guidelines to upload directly to the NDIS system, known arrestee and convicted offender DNA profiles, as well as cas
March 14, 2014 17:35
Clinical study in international headache journal finds electroCore’s non invasive vagus nerve stimulation effective in treating migraine
A study reported (13TH March 2014) in the International Headache Society’s official journal Cephalalgia found that the use of electroCore’s non invasive vagus nerve stimulation therapy (nVNS) may be a
March 14, 2014 17:35
Quintiles Announces Pricing of Secondary Public Offering
Quintiles today announced the pricing of a secondary public offering of 15 million shares of its common stock by certain of its shareholders at a price to the public of $52.00 per share. In addition,
March 13, 2014 15:20
STC life, Co., Ltd. Successfully Treats Canadian Pulmonary Fibrosis Patient at 97.7 B&H Hospital Stem Cell Center
Stem cell research institute of STC Life Co., Ltd. (http://stclife.com/en/lab/lnb01.html) (Chairman: KYE HO LEE) and 97.7 B&H Clinic (Representative Doctor: WON JU JUNG) successfully finished mesenchy
March 12, 2014 17:20
Quintiles Honored as ‘Best CRO in Asia’ for 3rd Time in Four Years
Quintiles last night was named the “Best CRO in Asia” at the 2014 BioPharma Asia Industry Awards dinner, the third time in the event’s four-year history that Quintiles has received the honor. The awar
March 12, 2014 17:00
Mentor Capital Acquires 60% of Bhang Chocolate for $39 Million
Mentor Capital, Inc. (OTC Markets: MNTR) announced today that it has been selected by Bhang Chocolate Company, Inc. to provide $39 Million in equity funding for Bhang’s national and international expa
March 11, 2014 15:55
Quintiles Announces Launch of Secondary Public Offering of Common Stock
Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE:Q) announced today the launch of a secondary public offering of its common stock. Certain shareholders of Quintiles (the “Selling Shareholders
25 per page50 per page75 per page100 per page